Literature DB >> 18208931

Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.

Bernardo Dell'osso1, Emanuela Mundo, Donatella Marazziti, A Carlo Altamura.   

Abstract

Obsessive compulsive disorder (OCD) is a chronic disorder, currently recognized as one of the most common psychiatric disorder as well as one of the most disabling of all medical disorders. OCD is characterized by high rates of partial and/or absent response to standard, recommended treatments (serotonin reuptake inhibitors and psychotherapy). Recent investigation showed that Venlafaxine, a dual serotonin and norepinephrine reuptake inhibitor (SNRI), may be a valid alternative for some treatment-refractory patients. We present the cases of four OCD patients with comorbid mood or anxiety disorders, who were treated with serotonin reuptake inhibitors (SRIs) at adequate doses for at least 12 weeks, showing partial/no response. Patients were then switched to Duloxetine up to 120 mg/day and followed up for 12 weeks. Three out of four patients showed a Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score reduction >or=35%. Duloxetine may be helpful in patients with treatment-resistant OCD, although larger and controlled studies are warranted to confirm this preliminary observation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208931     DOI: 10.1177/0269881107079865

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  11 in total

1.  SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2011-06

2.  The role of duloxetine in the treatment of anxiety disorders.

Authors:  Domenico De Berardis; Nicola Serroni; Alessandro Carano; Marco Scali; Alessandro Valchera; Daniela Campanella; Alessandro D'Albenzio; Berardo Di Giuseppe; Francesco Saverio Moschetta; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

Review 3.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

4.  Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.

Authors:  Debra L Safer; Katherine D Arnow
Journal:  Innov Clin Neurosci       Date:  2012-03

5.  Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series.

Authors:  Michele Fornaro
Journal:  Ann Gen Psychiatry       Date:  2011-02-28       Impact factor: 3.455

6.  Current management of obsessive and phobic states.

Authors:  Serena Goljevscek; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-30       Impact factor: 2.570

7.  Psychotherapy and medication management strategies for obsessive-compulsive disorder.

Authors:  Kelda H Walsh; Christopher J McDougle
Journal:  Neuropsychiatr Dis Treat       Date:  2011-08-23       Impact factor: 2.570

Review 8.  Drug treatment of obsessive-compulsive disorder.

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

9.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

Review 10.  Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Antonio Del Casale; Serena Sorice; Alessio Padovano; Maurizio Simmaco; Stefano Ferracuti; Dorian A Lamis; Chiara Rapinesi; Gabriele Sani; Paolo Girardi; Georgios D Kotzalidis; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.